SCHEMBL319282

SCHEMBL319282

CCCn1cc[n+](C)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.45
CA1 P00915 6/20 0.41
CA2 P00918 6/20 0.41
KMT2A Q03164 3/20 0.38
EEF2K O00418 2/20 0.38
EEF2 P13639 2/20 0.38
MEN1 O00255 2/20 0.38
PLK4 O00444 1/20 0.38
JAK2 O60674 1/20 0.38
EGFR P00533 1/20 0.38
TYK2 P29597 1/20 0.38
FLT3 P36888 1/20 0.38
BLM P54132 1/20 0.38
ITK Q08881 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
HDAC8 Q9BY41 4/20 0.37
POLB P06746 2/20 0.34
APOBEC3A P31941 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL15365841 0.98 ACHE (0.44) ACHECA1CA2KMT2AEEF2K
Bromide SCHEMBL8204076 0.98 CA1 (0.44) ACHECA1CA2KMT2AEEF2K
Iodide SCHEMBL302515 0.98 ACHE (0.44) ACHECA1CA2KMT2AEEF2K
Fluoride Ion SCHEMBL21980194 0.98 ACHE (0.44) ACHECA1CA2KMT2AEEF2K
Hydrochloric Acid SCHEMBL1884666 0.98 ACHE (0.47) ACHECA1CA2KMT2AEEF2K
SCHEMBL15732265 0.92 ACHE (0.41) ACHECA1CA2KMT2AEEF2K
SCHEMBL28698375 0.92 ACHE (0.41) ACHECA1CA2KMT2AEEF2K
SCHEMBL61367 0.92 LMNA (0.42) ACHECA1CA2KMT2AEEF2K
SCHEMBL15348251 0.92 ACHE (0.41) ACHECA1CA2KMT2AEEF2K
SCHEMBL294425 0.88 KMT2A (0.46) ACHECA1CA2KMT2AEEF2K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1696 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251133-B1 WIDE OPERATING TEMPERATURE RANGE (0° TO 275°C) ULTRACAPACITOR FASTCAP ULTRACAPACITORS LLC (US) 2025-12-24 EP claimed
EP-4614540-A2 CHIP FORM ULTRACAPACITOR FastCAP Ultracapacitors LLC (US) 2025-09-10 EP claimed
US-20250179894-A1 POWER SYSTEM FOR HIGH TEMPERATURE APPLICATIONS WITH RECHARGEABLE ENERGY STORAGE FASTCAP ULTRACAPACITORS LLC 2025-06-05 US claimed
WO-2025089809-A1 METHOD FOR MANUFACTURING SULFIDE-POLYMER HYBRID ELECTROLYTE MEMBRANE AND HYBRID ELECTROLYTE MEMBRANE MANUFACTURED THEREBY 한국전기연구원 2025-05-01 WO claimed
US-20250113829-A1 HIGH MOLECULAR WEIGHT MODIFIED RNA COMPOSITIONS nanoSUR LLC 2025-04-10 US claimed
US-20250069821-A1 CHIP FORM ULTRACAPACITOR FASTCAP ULTRACAPACITORS LLC 2025-02-27 US claimed
US-12215572-B2 Power system for high temperature applications with rechargeable energy storage FASTCAP ULTRACAPACITORS LLC (US) 2025-02-04 US claimed
CN-117895067-A Self-healing gel polymer electrolyte, preparation method and application thereof, and polymer lithium battery 吉林省东驰新能源科技有限公司 2024-04-16 CN claimed
US-11923139-B2 Energy storage device for high temperature applications ENI S.P.A. (IT) 2024-03-05 US claimed
CN-117551244-A Block polymer, preparation method and application thereof, solid electrolyte and application thereof 吉林省翰驰科技有限公司 2024-02-13 CN claimed
WO-2006027069-A1 METHOD FOR PRODUCING HETEROCYCLIC QUATERNARY AMMONIUM AND/OR GUANIDINIUM COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2006-03-16 WO claimed
US-20050287555-A1 Uses of cationic salts for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. 2005-12-29 US claimed
US-20050232981-A1 Compositions capable of facilitating penetration across a biological barrier CHIASMA, INC. 2005-10-20 US claimed
WO-2005094785-A2 COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER CHIASMA, LTD. (IL) 2005-10-13 WO claimed
US-20050136103-A1 Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation CHIASMA, INC. 2005-06-23 US claimed
US-20050058702-A1 Compositions capable of facilitating penetration across a biological barrier CHIASMA, INC. 2005-03-17 US claimed
US-20040146549-A1 Amino acid sequences capable of facilitating penetration across a biological barrier CHIASMA, INC. 2004-07-29 US claimed
US-20040009393-A1 Electrolyte of lithium-sulfur batteries and lithium-sulfur batteries comprising the same SAMSUNG SDI CO., LTD (KR) 2004-01-15 US claimed
US-20030073005-A1 Electrolyte for lithium-sulfur batteries and lithium-sulfur batteries comprising the same SAMSUNG SDI CO., LTD. (KR) 2003-04-17 US claimed
EP-1302997-A2 An electrolyte for lithium-sulfur batteries and lithium-sulfur batteries containing the same Samsung SDI Co., Ltd. (KR) 2003-04-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250113829-A1 HIGH MOLECULAR WEIGHT MODIFIED RNA COMPOSITIONS NSUN2, NSUN3, RNGTT ACHE 4757/4885CA1 4858/4885CA2 4844/4885
US-20050136103-A1 Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation CFTR, SLC47A1, SLC47A2 ACHE 2464/4885CA1 3738/4885CA2 1099/4885
US-20050232981-A1 Compositions capable of facilitating penetration across a biological barrier MMP8, PGF, AQP1 ACHE 3697/4885CA1 2085/4885CA2 2227/4885
US-20040146549-A1 Amino acid sequences capable of facilitating penetration across a biological barrier SLC7A1, SLC1A5, SLC3A2 ACHE 4856/4885CA1 3512/4885CA2 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.